oasis 1 trial semaglutide 4 In the OASIS 4 phase 3 trial, once-daily oral semaglutide at 🥼🧪Slide Deck: Efficacy and safety

Identifying and applying materials that suppress LCT-induced GIP hypersecretion, such as MCTs, may therefore prevent the onset and progression of diet-induced obesity

The headline finding was in breast cancer

The STEP 1 trial found that nausea was reported by 44% of participants in the semaglutide group, but the vast majority of nausea episodes were transient and occurred during dose escalation

doi:10.1093/bioinformatics/btv033 26

Sublingual peptides dramatically reduce these compliance barriers

I love that Chris checks in with me periodically and I am having even better results than expected from his suggested medication in terms of energy levels and weight loss